Why Iovance Biotherapeutics Inc (IOVA) Stock Is Rising
As of 2026-11-12, Iovance Biotherapeutics Inc (IOVA) has a next-year EPS growth estimate of 75.22%. Featured in 4 EPS revision reports, most recently on 2026-10-02.
Why IOVA Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Iovance Biotherapeutics Inc's next-year EPS growth estimate from 62.06% to 71.03% on 2026-11-05.
- →Estimate Trending Higher: Since detection, the estimate has moved up a net +4.19 pp to 75.22% across 1 upward revision.
- !Largest Single-Day Revision: +4.19 pp on 2026-11-06 (71.03% → 75.22%).
- ·Current-Year Growth: Projected at 64.84%, supporting the forward estimate revision.
News Context
The primary structural driver appears to be the late-October upward revision to next-year EPS growth estimates, which rose slightly to 61.67% and have since accumulated a net +7.89 pp change to 69.56%. That revision followed Iovance’s Q3 2026 report showing record revenue of about $122M and 60%
Generated 2026-11-06 · news as of 2026-11-06
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 75.22%
- EPS growth this year
- 64.84%
- EPS next quarter (est)
- -$0.04
- Last price
- $7.63
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 75.22% | 64.84% | -$0.04 | $7.63 |
| 2026-11-11 | 75.22% | 64.84% | -$0.04 | $8.09 |
| 2026-11-10 | 75.22% | 64.84% | -$0.04 | $8.08 |
| 2026-11-09 | 75.22% | 64.84% | -$0.04 | $8.17 |
| 2026-11-07 | 75.22% | 64.84% | -$0.04 | $8.04 |
| 2026-11-06 | 75.22% | 64.84% | -$0.04 | $8.04 |
| 2026-11-05 | 71.03% | 62.94% | -$0.05 | $7.74 |
| 2026-11-04 | 62.06% | 59.44% | -$0.08 | $8.70 |
| 2026-11-03 | 62.06% | 59.44% | -$0.08 | $8.83 |
| 2026-11-02 | 61.67% | 59.31% | -$0.08 | $8.02 |
| 2026-10-31 | 61.67% | 59.31% | -$0.08 | $8.48 |
| 2026-10-30 | 61.67% | 59.31% | -$0.08 | $8.48 |
| 2026-10-29 | 61.54% | 59.31% | -$0.08 | $9.56 |
| 2026-10-28 | 61.54% | 59.31% | -$0.08 | $14.81 |
| 2026-10-27 | 61.54% | 59.31% | -$0.08 | $14.58 |
| 2026-10-26 | 61.54% | 59.31% | -$0.08 | $13.78 |
| 2026-10-23 | 61.46% | 59.29% | -$0.08 | $14.09 |
| 2026-10-22 | 61.46% | 59.29% | -$0.08 | $14.14 |
| 2026-10-21 | 61.46% | 59.29% | -$0.08 | $14.62 |
| 2026-10-20 | 61.46% | 59.29% | -$0.08 | $14.86 |
| 2026-10-19 | 61.46% | 59.29% | -$0.08 | $14.21 |
| 2026-10-16 | 61.46% | 59.29% | -$0.08 | $13.62 |
| 2026-10-15 | 61.46% | 59.29% | -$0.08 | $14.72 |
| 2026-10-14 | 61.46% | 59.29% | -$0.08 | $14.21 |
| 2026-10-13 | 61.46% | 59.29% | -$0.08 | $14.50 |
| 2026-10-12 | 60.11% | 58.88% | -$0.09 | $14.56 |
| 2026-10-11 | 58.20% | 58.90% | -$0.09 | $14.62 |
| 2026-10-10 | 58.20% | 58.90% | -$0.09 | $14.62 |
| 2026-10-09 | 58.20% | 58.90% | -$0.09 | $14.62 |
| 2026-10-08 | 58.20% | 58.90% | -$0.09 | $13.31 |
Reports Featuring IOVA
- 2026-10-02
Healthcare Stocks Lead: IMMP Surges 1573%, IOVA Jumps 31.7% After EPS Revisions
- 2026-10-01
IMMP Soars 1646% as IOVA, LITE Lead Post-EPS Revision Surge
- 2026-09-30
IMMP Soars 1688% as EPS Revisions Ignite Biotech Rally; IOVA Jumps 37%
- 2026-09-29
IOVA Jumps 33.8% on Raised 2026 Outlook; CBRL, AMAT Lead EPS Revision Rally
Recent News
- Iovance Beats With Record Quarter And 60% Gross Margin, But Reaffirmed Guide Implies A Flat Fourth QuarterEarnings Whispers
- Iovance Biotherapeutics: Q3 Earnings SnapshotAssociated Press
- Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate UpdatesGlobeNewswire
- SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In FocusStocktwits
- SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3Stocktwits
- SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3Stocktwits
- IOVA Stock Heads For Worst Day In Over 17 Months, Retail Says Selling Is Not Done Whats Driving The Fall?Stocktwits
- IOVA Stock Heads For Worst Day In Over 17 Months, Retail Says Selling Is Not Done Whats Driving The Fall?Stocktwits
- Iovance stock falls after lung cancer trial data disappointsInvesting.com
- Iovance stock falls after lung cancer trial data disappointsInvesting.com
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Iovance Biotherapeutics Inc (IOVA) stock go up recently?▾
Iovance Biotherapeutics Inc (IOVA) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 62.06% to 71.03% on 2026-11-05. Since detection, the estimate has moved up a net +4.19 pp to 75.22%. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Iovance Biotherapeutics Inc's next-year EPS growth estimate?▾
As of 2026-11-12, Iovance Biotherapeutics Inc (IOVA) has a next-year EPS growth estimate of 75.22%, based on analyst consensus.
When was the latest EPS estimate revision for IOVA?▾
The most recent revision occurred on 2026-11-06, when analysts adjusted the next-year EPS growth estimate from 71.03% to 75.22%.
What sector and industry does Iovance Biotherapeutics Inc belong to?▾
Iovance Biotherapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. IOVA appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Iovance Biotherapeutics Inc (IOVA) appears here because it was detected by our daily top-EPS-revision-performer screen.